Treatment of gestational trophoblastic disease.
Gestational trophoblastic disease (GTD) forms a spectrum of illness from the borderline malignancy of hydatidiform mole to the highly aggressive behaviour of choriocarcinoma. In the past, many women have died from this group of disorders. However, during the last 45 years highly effective chemotherapy regimens have been developed which can be appropriately tailored to the individual patient's risk of becoming resistant to the treatment. As a result, the management of GTD is one of the modern success stories in oncology. Today, with an integrated approach to management few women die from their trophoblastic tumours.
Seckl
M J
MJ
Gestational Trophoblastic Disease Centre, Department of Medical Oncology, Charing Cross Hospital, London, UK.
Newlands
E S
ES
D000328:Adult; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002822:Choriocarcinoma / Q000000981:diagnostic imaging; D006063:Chorionic Gonadotropin / Q000097:blood; D003267:Contraception; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D006828:Hydatidiform Mole / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D011247:Pregnancy; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014328:Trophoblastic Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018245:Trophoblastic Tumor, Placental Site / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology
D006063:Chorionic Gonadotropin